XINGANJIANG
873167
INNOVATIVE DATA
835305
CHENGUANG MEDICAL
430300
4
Hangzhou Gaoxin Materials Technology
300478
5
Beijing Philisense Technology
300287
(FY)Dec 31, 2024 | (Q4)Dec 31, 2024 | (Q3)Sep 30, 2024 | (Q2)Jun 30, 2024 | (Q1)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q4)Dec 31, 2023 | (Q3)Sep 30, 2023 | (Q2)Jun 30, 2023 | (Q1)Mar 31, 2023 | |
---|---|---|---|---|---|---|---|---|---|---|
Operating Cash Flow (Indirect Method) | ||||||||||
Cash flow from continuing operating activities | -3.67%1.42B | 20.14%167M | -0.24%409M | -3.84%401M | -12.82%442M | 4.25%1.47B | 65.48%139M | -43.06%410M | -4.79%417M | 196.49%507M |
Net income from continuing operations | 8.77%980M | 17.76%126M | 19.48%319M | 6.54%228M | -1.92%307M | 88.49%901M | 84.48%107M | 17.62%267M | 157.83%214M | 184.55%313M |
Operating gains losses | -200.00%-45M | -53.33%7M | -1,900.00%-36M | -166.67%-8M | -150.00%-8M | 60.71%45M | 287.50%15M | -88.24%2M | 163.16%12M | -57.89%16M |
Depreciation and amortization | 5.08%476M | 6.14%121M | 8.11%120M | 5.36%118M | 0.86%117M | -24.75%453M | -15.56%114M | -26.00%111M | -26.80%112M | -29.27%116M |
Deferred tax | 30.00%-7M | 25.00%-3M | 89.47%-2M | -133.33%-2M | --0 | 50.00%-10M | 69.23%-4M | ---19M | 175.00%6M | 600.00%7M |
Other non cash items | 11.83%378M | 7.23%89M | 20.22%107M | -9.21%69M | 25.56%113M | -17.96%338M | -7.78%83M | -6.32%89M | -26.92%76M | -26.83%90M |
Change In working capital | -26.82%-454M | 2.87%-203M | -103.51%-116M | 5.41%-35M | -81.82%-100M | -113.10%-358M | -3.98%-209M | -127.14%-57M | -136.63%-37M | 80.22%-55M |
-Change in receivables | -50.00%-9M | -25.00%-5M | 125.00%1M | 33.33%-2M | -160.00%-3M | -500.00%-6M | -180.00%-4M | -136.36%-4M | 80.00%-3M | 350.00%5M |
-Change in inventory | 142.11%8M | -1,116.67%-61M | 165.38%17M | 43.59%-22M | 85.00%74M | 0.00%-19M | 106.67%6M | -316.67%-26M | -34.48%-39M | -54.55%40M |
-Change in prepaid assets | 22.86%-27M | -20.00%-30M | 206.90%31M | -385.71%-20M | -166.67%-8M | -116.91%-35M | -177.78%-25M | -115.10%-29M | 150.00%7M | -68.42%12M |
-Change in payables and accrued expense | -113.76%-15M | 101.35%1M | -165.38%-68M | 18.56%115M | -250.00%-63M | 165.85%109M | -640.00%-74M | 8.33%104M | -61.35%97M | 93.92%-18M |
-Change in other current liabilities | -0.98%-411M | 3.57%-108M | 4.90%-97M | -7.07%-106M | -6.38%-100M | -2.78%-407M | -15.46%-112M | -0.99%-102M | -7.61%-99M | 11.32%-94M |
Cash from discontinued investing activities | ||||||||||
Operating cash flow | -3.67%1.42B | 20.14%167M | -0.24%409M | -3.84%401M | -12.82%442M | 4.25%1.47B | 65.48%139M | -43.06%410M | -4.79%417M | 196.49%507M |
Investing cash flow | ||||||||||
Cash flow from continuing investing activities | 76.04%-178M | -148.54%-150M | 122.91%104M | -36.69%-231M | 123.08%99M | -42.34%-743M | 335.21%309M | 16.08%-454M | -160.00%-169M | -3,400.00%-429M |
Capital expenditure reported | 0.70%-705M | 13.74%-182M | 1.20%-165M | -10.46%-169M | -5.59%-189M | -4.57%-710M | -24.12%-211M | -3.09%-167M | -7.75%-153M | 12.68%-179M |
Net business purchase and sale | --0 | ---- | ---- | ---- | ---- | --0 | ---- | ---- | ---- | ---- |
Net investment purchase and sale | 1,476.32%523M | -93.83%32M | 192.73%268M | -300.00%-64M | 213.89%287M | -121.59%-38M | 116.25%519M | 23.95%-289M | -121.05%-16M | -205.00%-252M |
Net other investing changes | -20.00%4M | --0 | -50.00%1M | --2M | -50.00%1M | 25.00%5M | 0.00%1M | 100.00%2M | --0 | 100.00%2M |
Cash from discontinued investing activities | ||||||||||
Investing cash flow | 76.04%-178M | -148.54%-150M | 122.91%104M | -36.69%-231M | 123.08%99M | -42.34%-743M | 335.21%309M | 16.08%-454M | -160.00%-169M | -3,400.00%-429M |
Financing cash flow | ||||||||||
Cash flow from continuing financing activities | -128.49%-1.64B | -0.21%-477M | -3,640.00%-374M | 93.13%-9M | -683.84%-776M | 15.17%-716M | -82.38%-476M | 85.71%-10M | 45.19%-131M | 63.87%-99M |
Net issuance payments of debt | -123.78%-39M | -272.92%-179M | -154.25%-115M | ---- | ---- | 8,100.00%164M | -2,500.00%-48M | --212M | ---- | ---- |
Net common stock issuance | -103.75%-1.25B | 42.34%-192M | -18.99%-188M | -206.45%-190M | -1,031.67%-679M | -31.55%-613M | -505.45%-333M | -1,336.36%-158M | 64.77%-62M | 73.21%-60M |
Cash dividends paid | -14.81%-248M | -12.96%-61M | -12.96%-61M | -14.81%-62M | -18.52%-64M | -6.93%-216M | -8.00%-54M | -5.88%-54M | -8.00%-54M | -5.88%-54M |
Net other financing activities | -96.08%-100M | -9.76%-45M | ---10M | ---12M | -320.00%-33M | 71.35%-51M | 74.05%-41M | ---- | ---- | 1,400.00%15M |
Cash from discontinued financing activities | ||||||||||
Financing cash flow | -128.49%-1.64B | -0.21%-477M | -3,640.00%-374M | 93.13%-9M | -683.84%-776M | 15.17%-716M | -82.38%-476M | 85.71%-10M | 45.19%-131M | 63.87%-99M |
Net cash flow | ||||||||||
Beginning cash position | -0.18%1.13B | 5.48%1.19B | -12.28%1.04B | -20.52%883M | -0.18%1.13B | -0.53%1.13B | -6.61%1.13B | 3.66%1.19B | 6.11%1.11B | -0.53%1.13B |
Current changes in cash | -2,921.43%-395M | -1,542.86%-460M | 357.41%139M | 37.61%161M | -1,019.05%-235M | -70.21%14M | 73.58%-28M | -149.54%-54M | -12.69%117M | 76.67%-21M |
Effect of exchange rate changes | 37.50%-10M | -140.00%-10M | 375.00%11M | 97.44%-1M | -600.00%-10M | 69.81%-16M | 0.00%25M | 91.11%-4M | -14.71%-39M | 100.00%2M |
End cash Position | -35.90%723M | -35.90%723M | 5.48%1.19B | -12.28%1.04B | -20.52%883M | -0.18%1.13B | -0.18%1.13B | -6.61%1.13B | 3.66%1.19B | 6.11%1.11B |
Free cash flow | -6.42%714M | 79.17%-15M | 0.41%244M | -12.12%232M | -22.87%253M | 3.95%763M | 16.28%-72M | -56.45%243M | -10.81%264M | 1,064.71%328M |
Currency Unit | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD |
Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
Audit Opinions | -- | -- | -- | -- | -- | Unqualified Opinion | -- | -- | -- | -- |